Skip to main content

Table 3 Toxicity and supportive care - supportive treatment.

From: A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

 

CP

N= 90

CLD

N = 87

Antibiotics

9 (10)

14 (16)

Granulocyte colony-stimulating factor

41 (46)

45 (52)

RBC transfusion †

3 (3)

12 (14)

Platelet transfusion

0 (0)

3 (3)

Hospitalization

11 (12)

13 (15)

  1. † Red blood cell (RBC) transfusion rate is higher among patients treated in group B (3% in group A versus 14% in group B, P = 0.015)